Hemolytic Uremic Syndrome clinical trials

Explore recruiting hemolytic uremic syndrome clinical trials.

Recruiting hemolytic uremic syndrome studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hemolytic Uremic Syndrome trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III study to evaluate the efficacy of INM004 (Shiga antitoxin) in pediatric patients with Hemolytic Uremic Syndrome associated to infection by Shiga toxin-producing Escherichia coli

Italy, Netherlands, Germany, Ireland, Belgium, Romania +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients with atypical Hemolytic Uremic Syndrome (aHUS)

Germany, Hungary, Spain, Poland, Italy, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy

Slovenia, Slovakia, Czechia, Greece, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, single arm, open-label study to evaluate efficacy and safety of switching from anti-C5 antibody therapy to iptacopan therapy in study participants with aHUS

Italy, Spain, Germany, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Belgium, Spain, Italy, France, Hungary, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hemolytic Uremic Syndrome trials by city

Hemolytic Uremic Syndrome in Toronto Hemolytic Uremic Syndrome in Vancouver Hemolytic Uremic Syndrome in Montreal Hemolytic Uremic Syndrome in Calgary Hemolytic Uremic Syndrome in Edmonton Hemolytic Uremic Syndrome in Ottawa Hemolytic Uremic Syndrome in Winnipeg Hemolytic Uremic Syndrome in Quebec City Hemolytic Uremic Syndrome in Hamilton Hemolytic Uremic Syndrome in Kitchener Hemolytic Uremic Syndrome in London Hemolytic Uremic Syndrome in Halifax Hemolytic Uremic Syndrome in New York Hemolytic Uremic Syndrome in Los Angeles Hemolytic Uremic Syndrome in Chicago Hemolytic Uremic Syndrome in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease